Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
There is a pressing need for continuous improvement and innovation in food safety systems to keep pace with emerging food trends and habits
Apollo Transplant program is the first program in India to cross the landmark of 18500 kidney transplants, 4300 liver transplants and 500 pediatric liver transplants
Good momentum in commercial CDMO business
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
The agreement extends the customer's suite of cloud DevOps, data engineering, and data platform management solutions
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Subscribe To Our Newsletter & Stay Updated